CD274 and renal cell carcinoma: Immune checkpoint inhibitors that block PD-1 and PD-L1 have exhibited remarkable efficacy with respect to the treatment of refractory solid tumours including melanoma and RCC, and substantial attention has been paid to assessing PD-L1 expression in STS.